Cargando…

The presence and impact of multimorbidity clusters on adverse outcomes across the spectrum of kidney function

BACKGROUND: Multimorbidity (the presence of two or more chronic conditions) is common amongst people with chronic kidney disease, but it is unclear which conditions cluster together and if this changes as kidney function declines. We explored which clusters of conditions are associated with differen...

Descripción completa

Detalles Bibliográficos
Autores principales: Sullivan, Michael K., Carrero, Juan-Jesus, Jani, Bhautesh Dinesh, Anderson, Craig, McConnachie, Alex, Hanlon, Peter, Nitsch, Dorothea, McAllister, David A., Mair, Frances S., Mark, Patrick B., Gasparini, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623942/
https://www.ncbi.nlm.nih.gov/pubmed/36320059
http://dx.doi.org/10.1186/s12916-022-02628-2
_version_ 1784822119659470848
author Sullivan, Michael K.
Carrero, Juan-Jesus
Jani, Bhautesh Dinesh
Anderson, Craig
McConnachie, Alex
Hanlon, Peter
Nitsch, Dorothea
McAllister, David A.
Mair, Frances S.
Mark, Patrick B.
Gasparini, Alessandro
author_facet Sullivan, Michael K.
Carrero, Juan-Jesus
Jani, Bhautesh Dinesh
Anderson, Craig
McConnachie, Alex
Hanlon, Peter
Nitsch, Dorothea
McAllister, David A.
Mair, Frances S.
Mark, Patrick B.
Gasparini, Alessandro
author_sort Sullivan, Michael K.
collection PubMed
description BACKGROUND: Multimorbidity (the presence of two or more chronic conditions) is common amongst people with chronic kidney disease, but it is unclear which conditions cluster together and if this changes as kidney function declines. We explored which clusters of conditions are associated with different estimated glomerular filtration rates (eGFRs) and studied associations between these clusters and adverse outcomes. METHODS: Two population-based cohort studies were used: the Stockholm Creatinine Measurements project (SCREAM, Sweden, 2006–2018) and the Secure Anonymised Information Linkage Databank (SAIL, Wales, 2006–2021). We studied participants in SCREAM (404,681 adults) and SAIL (533,362) whose eGFR declined lower than thresholds (90, 75, 60, 45, 30 and 15 mL/min/1.73m(2)). Clusters based on 27 chronic conditions were identified. We described the most common chronic condition(s) in each cluster and studied their association with adverse outcomes using Cox proportional hazards models (all-cause mortality (ACM) and major adverse cardiovascular events (MACE)). RESULTS: Chronic conditions became more common and clustered differently across lower eGFR categories. At eGFR 90, 75, and 60 mL/min/1.73m(2), most participants were in large clusters with no prominent conditions. At eGFR 15 and 30 mL/min/1.73m(2), clusters involving cardiovascular conditions were larger and were at the highest risk of adverse outcomes. At eGFR 30 mL/min/1.73m(2), in the heart failure, peripheral vascular disease and diabetes cluster in SCREAM, ACM hazard ratio (HR) is 2.66 (95% confidence interval (CI) 2.31–3.07) and MACE HR is 4.18 (CI 3.65–4.78); in the heart failure and atrial fibrillation cluster in SAIL, ACM HR is 2.23 (CI 2.04 to 2.44) and MACE HR is 3.43 (CI 3.22–3.64). Chronic pain and depression were common and associated with adverse outcomes when combined with physical conditions. At eGFR 30 mL/min/1.73m(2), in the chronic pain, heart failure and myocardial infarction cluster in SCREAM, ACM HR is 2.00 (CI 1.62–2.46) and MACE HR is 4.09 (CI 3.39–4.93); in the depression, chronic pain and stroke cluster in SAIL, ACM HR is 1.38 (CI 1.18–1.61) and MACE HR is 1.58 (CI 1.42–1.76). CONCLUSIONS: Patterns of multimorbidity and corresponding risk of adverse outcomes varied with declining eGFR. While diabetes and cardiovascular disease are known high-risk conditions, chronic pain and depression emerged as important conditions and associated with adverse outcomes when combined with physical conditions. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-022-02628-2.
format Online
Article
Text
id pubmed-9623942
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96239422022-11-02 The presence and impact of multimorbidity clusters on adverse outcomes across the spectrum of kidney function Sullivan, Michael K. Carrero, Juan-Jesus Jani, Bhautesh Dinesh Anderson, Craig McConnachie, Alex Hanlon, Peter Nitsch, Dorothea McAllister, David A. Mair, Frances S. Mark, Patrick B. Gasparini, Alessandro BMC Med Research Article BACKGROUND: Multimorbidity (the presence of two or more chronic conditions) is common amongst people with chronic kidney disease, but it is unclear which conditions cluster together and if this changes as kidney function declines. We explored which clusters of conditions are associated with different estimated glomerular filtration rates (eGFRs) and studied associations between these clusters and adverse outcomes. METHODS: Two population-based cohort studies were used: the Stockholm Creatinine Measurements project (SCREAM, Sweden, 2006–2018) and the Secure Anonymised Information Linkage Databank (SAIL, Wales, 2006–2021). We studied participants in SCREAM (404,681 adults) and SAIL (533,362) whose eGFR declined lower than thresholds (90, 75, 60, 45, 30 and 15 mL/min/1.73m(2)). Clusters based on 27 chronic conditions were identified. We described the most common chronic condition(s) in each cluster and studied their association with adverse outcomes using Cox proportional hazards models (all-cause mortality (ACM) and major adverse cardiovascular events (MACE)). RESULTS: Chronic conditions became more common and clustered differently across lower eGFR categories. At eGFR 90, 75, and 60 mL/min/1.73m(2), most participants were in large clusters with no prominent conditions. At eGFR 15 and 30 mL/min/1.73m(2), clusters involving cardiovascular conditions were larger and were at the highest risk of adverse outcomes. At eGFR 30 mL/min/1.73m(2), in the heart failure, peripheral vascular disease and diabetes cluster in SCREAM, ACM hazard ratio (HR) is 2.66 (95% confidence interval (CI) 2.31–3.07) and MACE HR is 4.18 (CI 3.65–4.78); in the heart failure and atrial fibrillation cluster in SAIL, ACM HR is 2.23 (CI 2.04 to 2.44) and MACE HR is 3.43 (CI 3.22–3.64). Chronic pain and depression were common and associated with adverse outcomes when combined with physical conditions. At eGFR 30 mL/min/1.73m(2), in the chronic pain, heart failure and myocardial infarction cluster in SCREAM, ACM HR is 2.00 (CI 1.62–2.46) and MACE HR is 4.09 (CI 3.39–4.93); in the depression, chronic pain and stroke cluster in SAIL, ACM HR is 1.38 (CI 1.18–1.61) and MACE HR is 1.58 (CI 1.42–1.76). CONCLUSIONS: Patterns of multimorbidity and corresponding risk of adverse outcomes varied with declining eGFR. While diabetes and cardiovascular disease are known high-risk conditions, chronic pain and depression emerged as important conditions and associated with adverse outcomes when combined with physical conditions. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-022-02628-2. BioMed Central 2022-11-01 /pmc/articles/PMC9623942/ /pubmed/36320059 http://dx.doi.org/10.1186/s12916-022-02628-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Sullivan, Michael K.
Carrero, Juan-Jesus
Jani, Bhautesh Dinesh
Anderson, Craig
McConnachie, Alex
Hanlon, Peter
Nitsch, Dorothea
McAllister, David A.
Mair, Frances S.
Mark, Patrick B.
Gasparini, Alessandro
The presence and impact of multimorbidity clusters on adverse outcomes across the spectrum of kidney function
title The presence and impact of multimorbidity clusters on adverse outcomes across the spectrum of kidney function
title_full The presence and impact of multimorbidity clusters on adverse outcomes across the spectrum of kidney function
title_fullStr The presence and impact of multimorbidity clusters on adverse outcomes across the spectrum of kidney function
title_full_unstemmed The presence and impact of multimorbidity clusters on adverse outcomes across the spectrum of kidney function
title_short The presence and impact of multimorbidity clusters on adverse outcomes across the spectrum of kidney function
title_sort presence and impact of multimorbidity clusters on adverse outcomes across the spectrum of kidney function
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623942/
https://www.ncbi.nlm.nih.gov/pubmed/36320059
http://dx.doi.org/10.1186/s12916-022-02628-2
work_keys_str_mv AT sullivanmichaelk thepresenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction
AT carrerojuanjesus thepresenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction
AT janibhauteshdinesh thepresenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction
AT andersoncraig thepresenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction
AT mcconnachiealex thepresenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction
AT hanlonpeter thepresenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction
AT nitschdorothea thepresenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction
AT mcallisterdavida thepresenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction
AT mairfrancess thepresenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction
AT markpatrickb thepresenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction
AT gasparinialessandro thepresenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction
AT sullivanmichaelk presenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction
AT carrerojuanjesus presenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction
AT janibhauteshdinesh presenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction
AT andersoncraig presenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction
AT mcconnachiealex presenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction
AT hanlonpeter presenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction
AT nitschdorothea presenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction
AT mcallisterdavida presenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction
AT mairfrancess presenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction
AT markpatrickb presenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction
AT gasparinialessandro presenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction